

University of Mosul  
College of Pharmacy



# **Mitochondrial Function and Biochemical Analysis of Type 2 Diabetes Patients on Metformin Therapy**

**A Thesis submitted**

**By**

**Samara Sameer Yonus**

**To The Council of the College of Pharmacy/University of Mosul  
As a Partial Fulfillment of the Requirements for the Master  
Degree in Pharmacy**

**Supervised by**

**Assistant Prof. Dr. Muhammad A. Al-Kataan**

---

**2022 A.D.**

**1443 A.H.**

## Summary

Type 2 diabetes (T2D) is a multisystemic, chronic metabolic disorder that affects a large number of people. It is characterized by mitochondrial dysfunction as well as the presence of oxidative stress and low levels of ATP. Metformin is one of the most effective anti-hyperglycemic agents used as first-line oral therapy for type 2 diabetes.

This study aims to explain changes in mitochondrial copy number, glycemic index, renal and liver status in type-2 diabetic patients treated with metformin monotherapy.

A retrospective case-control study was conducted at Al- Wafaa diabetic center in Mosul, from 1st January to June 2021. Forty-seven newly diagnosed type 2 diabetes mellitus patients aged between 25-65 years (23 males, 24 females) treated with metformin for 2-6 months in the dose was between (500 mg- 1000 mg) per day, and Forty-seven (20 males, 27 females), healthy subjects with matched age as a control group.

A Questioner was filled by each subject with important basic information, then a fasting blood sample was taken, and the following tests were done (glycated hemoglobin % , blood urea (mg/dl), serum uric acid (mg/dl), serum creatinine (mg/dl), serum aspartate aminotransferase (U/L), serum Alanine aminotransferase (U/L), aspartate aminotransferase/Alanine aminotransferase ratio, serum Alkaline phosphatase (U/L), serum total protein (g/dl), serum total bilirubin (mg/dl), serum lactate ( $\mu$ M), serum pyruvate ( $\mu$ M), and serum lactate/pyruvate ratio and mt-ND1 gene).

The results of the study reveal that the mean HbA1c level in diabetic subjects was significantly higher ( $7.76 \pm 1.94$ ) than in the control group ( $5.18 \pm 0.49$ )  $p \leq 0.001$ .

In diabetic subjects, the mean blood urea level was significantly higher ( $28.31 \pm 8.24$ ), compared to the control group ( $24.27 \pm 5.81$ )  $p < 0.01$ .

In comparison to the control group ( $0.88 \pm 0.08$ ), serum creatinine was significantly higher in diabetic subjects ( $0.94 \pm 0.20$ )  $p < 0.05$ .

There were no significant differences in serum uric acid levels between diabetic subjects ( $4.91 \pm 0.82$ ) and the control group ( $4.67 \pm 1.34$ )  $p > 0.05$ .

The liver function test parameters used in this study revealed a significant increase in serum Alanine aminotransferase in diabetic subjects ( $20.65 \pm 6.04$ ) compared to the control group ( $12.95 \pm 6.05$ )  $p=0.000$ . In diabetic subjects, serum total protein ( $5.80 \pm 0.48$ ) was less than in the control group ( $7.07 \pm 0.38$ ),  $p=0.000$ . And serum total bilirubin was significantly higher in the diabetic subjects ( $1.01 \pm 0.44$ ), compared to the control group ( $0.48 \pm 0.15$ ),  $p =0.000$ ,

there was a significantly increase in serum glutamic oxaloacetic transaminase/glutamic pyruvic transaminase ratio in the diabetic subjects ( $1.71 \pm 0.70$ ) in comparison to the control group ( $0.98 \pm 0.24$ )  $p=0.000$ .

There were no significant differences in serum glutamic oxaloacetic transaminase (GOT) levels in diabetic subjects ( $19.31 \pm 5.32$ ) compared to the control group ( $19.48 \pm 4.32$ )  $p=0.86$ , and serum Alkaline Phosphatase levels in diabetic subjects ( $168.51 \pm 51.95$ ) compared to the control group ( $157.80 \pm 33.19$ )  $p>0.05$ .

The mitochondrial function tests parameters used in this study showed that diabetic subjects had a significantly higher level of mean serum lactate ( $1556.02 \pm 315.94$ ) than the control group ( $1210.29 \pm 297.09$ ),  $p=0.000$ . In diabetic subjects, serum pyruvate levels were higher ( $73.68 \pm 13.94$ ) than in the control group ( $68.06 \pm 13.80$ ),  $p=0.000$ . and the diabetic subjects had a higher serum lactate/pyruvate ratio ( $21.12 \pm 1.52$ ) than the control group ( $17.75 \pm 1.75$ ),  $p=0.000$ .

The present study found that mitochondrial copy number significantly decreased by 32.8 fold in T2DM patients in comparison to the control group ( $p < 0.01$ ).

Blood HbA1c and serum Uric acid, serum Uric acid and serum Creatinine, serum Alanine aminotransferase and blood HbA1c, and serum Alkaline phosphatase and serum Total bilirubin all had a significant negative correlation in the patient group.

There was a significant positive correlation between serum Uric acid and serum Urea, blood HbA1c and serum Total protein, serum lactate and blood HbA1c, and serum lactate levels and GOT/Alanine aminotransferase in our study.

In conclusion, in comparison to non-diabetic controls, diabetic patients treated with mono-metformin treatment had a lower mitochondrial copy number and moderate renal and liver impairment.

## Contents

Subject	Page
Summary	I
List of subjects	IV
List of tables	IX
List of figures	X
List of Abbreviation	XII
<b>Chapter One: Introduction and Literature Review</b>	<b>1-42</b>
1.1. Diabetes mellitus	1
1.2. Epidemiology	2
1.3. Insulin resistance and metabolic syndrome	2
1.4. Diagnosis of Diabetes Mellitus	3
1.5. Classification of Diabetes	3
1.5.1. Type-1 Diabetes Mellitus	4
1.5.2. Type-2 Diabetes Mellitus	4
1.6. Diagnostic criteria of Diabetes Mellitus	5
1.6.1. Random Plasma Glucose	5
1.6.2. Fasting Blood Glucose	5
1.6.3. Oral Glucose Tolerance Test	6
1.6.4. Glycated Proteins Include	6
1.6.4.1 A.Glycated Hemoglobin	6
1.6.4.2 Mechanism of Glycation	7
1.6.4.3. B. Fructosamine (Glycated Serum Protein)	9
1.6.4.4. Chemistry of Fructosamine	9
1.6.4.5. Fructosamine in the assessment of glycaemic control	9
1.7. Risk Factors of T2DM Mellitus	10

1.8. Complications of Type 2 Diabetes Mellitus	11
1.8.1. Macrovascular complications	11
1.8.2. Microvascular Complications	12
1.9. Oral hypoglycemic agents	12
1.10. Therapeutic Goals for Glycemic Control in Diabetes Mellitus	14
1.11. Treatment of Type 2 diabetes mellitus	14
1.12. Pharmacological Therapy	15
1.13. Biguanides	18
1.14. Metformin-Background	18
1.14.1. Chemistry of Metformin	19
1.14.2. Mechanism action of Metformin	20
1.14.3. Dose of Metformin	20
1.14.4. Pharmacokinetics of Metformin	21
1.14.5. Adverse effects of metformin	21
1.14.5.1. A.GIT Effects	21
1.14.5.2. B. Lactic Acidosis	21
1.14.5.3. C. Vitamin B12 Deficiency	21
1.14.6. Contraindications of metformin	22
1.14.7. Drug Interactions of metformin	22
1.15. Oxidative stress in diabetes	22
1.16. Molecular mechanisms involved in the actions of metformin	23
1.16.1.A. Metformin and gluconeogenesis	24
1.16.2. B. Activation of Adenosine monophosphate activated protein kinase	26

Appendix questionnaire form	
Number:	
Date:	
Name:	
Age:	
Sex:	
Weight:	
Height:	
BMI:	
Type of diabetes mellitus:	
Duration:	
Type of treatment and Dose:	
Family history:	
Pregnancy:	
Alcohol drinking:	
Cigarette smoking:	
Blood pressure:	
History of disease:	
History of drugs:	
Chronic disease:	
Dietary factor:	
HbA1C previously:	
Supplement Or Not:	

- Wherrett, Diane K, Josephine Ho, Celine Huot, Laurent Legault, Meranda Nakhla, and Elizabeth Rosolowsky. 2018. "Type 1 Diabetes in Children and Adolescents." *Canadian Journal of Diabetes* 42: S234–46.
- Winn-Deen, Emily S, H David, G Sigler, and R Chavez. 1988. "Development of a Direct Assay for Alpha-Amylase." *Clinical Chemistry* 34 (10): 2005–8.
- Wolf, Achim, Daniel Dedman, Jennifer Campbell, Helen Booth, Darren Lunn, Jennifer Chapman, and Puja Myles. 2019. "Data Resource Profile: Clinical Practice Research Datalink (CPRD) Aurum." *International Journal of Epidemiology* 48 (6): 1740-1740G. <https://doi.org/10.1093/ije/dyz034>.
- Yanai, Hidekatsu, Hiroki Adachi, Mariko Hakoshima, and Hisayuki Katsuyama. 2021. "Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease." *International Journal of Molecular Sciences* . <https://doi.org/10.3390/ijms22179221>.
- Yang, Fan, Li Zhang, Hao Wu, Hongbin Zou, and Yujun Du. 2014. "Clinical Analysis of Cause, Treatment and Prognosis in Acute Kidney Injury Patients." Edited by Cephaz Tagumirwa Musabayane. *PLoS ONE* 9 (2): e85214. <https://doi.org/10.1371/journal.pone.0085214>.
- Yedla, Niharika, Mohammad Shafi Kuchay, and Ambrish Mithal. 2015. "Hemoglobin e Disease and Glycosylated Hemoglobin." *Indian Journal of Endocrinology and Metabolism* 19 (5): 683–85. <https://doi.org/10.4103/2230-8210.163211>.

- Yuwaki, Keiichi, Taichi Shimazu, Yoko Yamagiwa, Manami Inoue, Atsushi Goto, Taiki Yamaji, Motoki Iwasaki, Norie Sawada, Shoichiro Tsugane, and JPHC Study Group. 2019. “Association between Serum Liver Enzymes and All-cause Mortality: The Japan Public Health Center-based Prospective Study.” *Liver International* 39 (8): 1566–76.
- Zetterberg, Anders, Olle Larsson, and Klas G Wiman. 1995. “What Is the Restriction Point?” *Current Opinion in Cell Biology* 7 (6): 835–42.
- Zhang, Dan, Bo Zhu, Wei Zhang, Wei Wang, Dan Guo, Ligang Yang, and Lu Wang. 2017. “Total Bilirubin Level May Be a Biomarker of Nephropathy in Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies Based on MOOSE Compliant.” *Medicine* 96 (1).
- Zhong, Victor W., Juhaeri Juhaeri, Stephen R. Cole, Christina M. Shay, Penny Gordon-Larsen, Evangelos Kontopantelis, and Elizabeth J. Mayer-Davis. 2018. “HbA 1C Variability and Hypoglycemia Hospitalization in Adults with Type 1 and Type 2 Diabetes: A Nested Case-Control Study.” *Journal of Diabetes and Its Complications* 32 (2): 203–9. <https://doi.org/10.1016/j.jdiacomp.2017.10.008>.
- Zhou, Long, Huanhuan Liu, Xiaoxiao Wen, Yaguang Peng, Yu Tian, and Liancheng Zhao. 2017. “Effects of Metformin on Blood Pressure in Nondiabetic Patients: A Meta-Analysis of Randomized Controlled Trials.” *Journal of Hypertension* 35 (1): 18–26.
- Zhu, Bo, Xiaomei Wu, Yifei Bi, and Yang Yang. 2017. “Effect of Bilirubin Concentration on the Risk of Diabetic Complications: A Meta-Analysis of Epidemiologic Studies.” *Scientific Reports* 7 (1): 1–15.

Zimmet, Paul Z. 2017. "Diabetes and Its Drivers: The Largest Epidemic in Human History?" *Clinical Diabetes and Endocrinology* 3 (1): 1–8. <https://doi.org/10.1186/s40842-016-0039-3>.